Back to Search
Start Over
Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study.
- Source :
-
Journal of clinical lipidology [J Clin Lipidol] 2015 Sep-Oct; Vol. 9 (5), pp. 692-7. Date of Electronic Publication: 2015 Jul 11. - Publication Year :
- 2015
-
Abstract
- Background: New, safer, and more effective agents to treat hyperlipidemia and thereby prevent cardiovascular events are under research.<br />Objective: To evaluate the lipid-lowering effects and safety of a natural hypolipidemic compound, coenzyme A (CoA) capsule, in Chinese patients with moderate dyslipidemia, compared with pantethine.<br />Methods: Overall, 216 subjects (124 males and 92 females; age, 18-75 years) with moderate dyslipidemia (triglyceride [TG], 2.3-6.5 mmol/L) were randomly divided into 2 groups administered CoA 400 U/d (n = 111) or pantethine 600 U/d (n = 105). Blood lipoproteins, liver and renal function, blood glucose, and complete blood count were measured at baseline and after 4- and 8-week treatment.<br />Results: TG reduction was 26.0% with CoA and 17.4% with pantethine after 4 weeks and 33.3% and 16.5% after 8 weeks; compared with baseline, the reduction was significant (P < .01) in both groups. The difference between the 2 groups was significant at both 4 weeks (P = .0413) and 8 weeks (P < .001). Compared with baseline, total cholesterol and non-high-density lipoprotein cholesterol (non-HDL-C) were reduced, whereas HDL-C was increased with CoA after 8 weeks (all P < .05). Compared with pantethine, total cholesterol (P = .026) and non-HDL-C (P = .005) were significantly reduced after 8 weeks of CoA treatment. There was no statistical difference in low-density lipoprotein cholesterol or HDL-C between the 2 groups (P > .05) and no difference in blood glucose, hepatic or renal function, myopathy, or gastrointestinal tract symptoms.<br />Conclusions: CoA can improve TG and other lipoprotein parameters to a greater extent than pantethine in moderate dyslipidemia, with no obvious adverse effects.<br /> (Copyright © 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Adolescent
Adult
Aged
Coenzyme A therapeutic use
Double-Blind Method
Female
Humans
Hyperlipidemias blood
Lipoproteins blood
Male
Middle Aged
Pantetheine adverse effects
Pantetheine pharmacology
Pantetheine therapeutic use
Treatment Outcome
Triglycerides blood
Young Adult
Coenzyme A adverse effects
Coenzyme A pharmacology
Hyperlipidemias drug therapy
Pantetheine analogs & derivatives
Safety
Subjects
Details
- Language :
- English
- ISSN :
- 1933-2874
- Volume :
- 9
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Journal of clinical lipidology
- Publication Type :
- Academic Journal
- Accession number :
- 26350816
- Full Text :
- https://doi.org/10.1016/j.jacl.2015.07.003